Risk Factors Related to Esophageal Cancer, a Case-Control Study in Herat Province of Afghanistan

Sultan Eser ¹ , Su Özgür ² * , Nasar Ahmad Shayan ³ , Mohammed Haris Abdianwall ⁴

Cited by CrossRef: 1

1- Amissah O, Chen W, de Dieu Habimana J, Sun Y, Lin L, Liu Y, Wang L, Liu Z, Mukama O, Basnet R, Liu H, Li J, Ding X, Lv L, Chen M, Liang Y, Huang R, Li Z. NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route. Cancer Cell Int. 2024;24(1) [Crossref]

Submit Your Paper Notification Instructions for Authors Aims and Scope Editorial policies Editorial Board AIM old site Archive

About Us

A Monthly Peer-Reviewed Medical Journal Published by the Academy of Medical Sciences of the I.R. Iran; Indexed in PubMed/MEDLINE, ISI Web of Science, EMBASE, SCOPUS, CINHAL, PASCAL, CSA, SID, ISSN: Print 1029-2977, Online 1735-3947.The impact factor of Archives of Iranian Medicine according to Journal Citation Reports® (JCR®) 2016 is 1.20.